Eli Lilly’s once-weekly basal insulin shot, Onswik (insulin efsitora alfa-gobe), won U.S. FDA approval for patients with type 2 diabetes, setting up direct competitive pressure on Novo Nordisk’s longer-acting offerings. The approval gives clinicians a weekly injectable option designed to reduce injection frequency versus daily basal insulin regimens. The label positions weekly dosing as a potential adherence lever for people struggling with daily injections, while also raising the stakes for payers and formularies as both companies expand their longer-interval insulin portfolios. Lilly framed Onswik as a longer-acting alternative, with expectations that weekly administration could simplify treatment plans. For the broader biotech and diabetes pipeline, the approval also reinforces ongoing momentum in next-generation insulin formats that target patient convenience and persistence as much as pharmacology.